Sci. Adv.: Dynamically covalent lipid nanoparticles mediate CRISPR/Cas9 genome editing against choroidal neovascularization in mice

Authors：

Desheng Cao¹,Junliang Zhu¹, Yang Guo², Yang Zhou¹, Jia Zeng³, Yuanyuan Tu³, Ziyin Zhao¹, Laiqing Xie², E Song³*, Manhui Zhu³*, Lichen Yin¹*

Institutions：

¹Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China.

²Department of Ophthalmology, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.

³Department of Ophthalmology, Lixiang Eye Hospital of Soochow University, Suzhou 215002, China.

Abstract：

As an important modality for choroidal neovascularization (CNV) treatment, intravitreal injection of vascular endothelial growth factor A (VEGFA) inhibitors suffers from undesired response rate, low patient compliance, and ocular damage. Here, dynamically covalent lipid nanoparticles (LNPs) were engineered to mediate VEGFA gene editing and CNV treatment by codelivering Cas9 mRNA (mCas9) and single guide RNA (sgRNA) targeting VEGFA (sgVEGFA). A library of lipidoids bearing iminoboronate ester linkage was developed via facile “one-pot” synthesis, and the top-performing lipidoid-A₄B₃C₇ was formulated into LNP-A₄B₃C₇ with the highest mRNA transfection efficiency. Inside the diseased retinal pigment epithelial cells, LNPs were dissociated upon H₂O₂-triggered lipidoid degradation, facilitating mRNA/sgRNA release to potentiate the gene editing efficiency. In laser-induced CNV mice, mCas9/sgVEGFA@LNP-A₄B₃C₇ after single intravitreal injection led to pronounced VEGFA disruption and CNV area reduction, outperforming the clinical anti-VEGF drug in eliciting sustained therapeutic effect. This study establishes a robust nonviral platform for mRNA delivery and genome editing and renders a promising strategy for CNV treatment.

IF：

12.5

Link：

https://www.science.org/doi/10.1126/sciadv.adj0006